Here are the DEF 14A proxy statements from Viatris Inc. (VTRS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow VTRS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VTRS filings page.
Viatris Inc. presents its 2026 proxy statement and notice of annual meeting, combining a performance review with key voting items for shareholders. In 2025 the company generated $14.3 billion in total revenues, returned more than $1 billion to shareholders via dividends and buybacks, and completed 60 regional business development transactions, including acquiring Aculys Pharma in Japan.
The proxy highlights five positive Phase 3 data readouts, a pipeline that includes selatogrel and cenerimod, and a global footprint delivering more than 70 billion doses of medicine across over 165 countries and territories in 2025. It also describes an enterprise‑wide strategic review aimed at optimizing structure, resource allocation and efficiency to support long‑term growth.
Shareholders are asked to elect 13 directors, approve on a non‑binding basis 2025 compensation for named executive officers, and ratify Deloitte & Touche LLP as auditor for 2026. Governance themes include an independent Chair, 12 of 13 director nominees classified as independent, formation of a Strategic Review Committee, and continued board refreshment, with seven new directors appointed since December 2022. The filing notes strong shareholder engagement and that the 2025 Say‑on‑Pay proposal received approximately 95% support.